The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Aug. 1, 1:45 AM

Slide #6. TherapeuticsMD, Inc. Secondary Offering

Company: TherapeuticsMD, Inc. (AMEX:TXMD)
Date announced: 7/29/2014
Shares Offered: 8,600,000
Date of Pricing: 7/30/2014
Price Per Share: $4.67
Secondary Offering Details: TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company") today announced the launch of an underwritten public offering of $40 million of shares of its common stock. All of the shares in the offering are to be sold by the Company. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to an additional $6 million of shares of its common stock. - updated 7/30 - TherapeuticsMD, Inc. (NYSE MKT:TXMD) (the "Company") announced today the pricing of an underwritten public offering of approximately 8.6 million shares of its common stock, offered at a price of $4.67 per share. The gross proceeds to the Company from this offering are expected to be approximately $40.0 million, before deducting underwriting discounts, commissions and other estimated offering expenses payable by the Company. All of the shares in the offering are to be sold by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less the underwriting discount, up to approximately 1.3 million additional shares of its common stock. The offering is expected to close on or about August 4, 2014, subject to the satisfaction of customary closing conditions.

TherapeuticsMD is a women's healthcare product company focused on creating and commercializing products targeted for women. Co. provides a range of products targeted for women's health specifically associated with pregnancy, child birth, nursing, post-child birth, and menopause, including prescription and over-the-counter prenatal vitamins, vegan docosahexaenoic acid, iron supplements, vitamin D supplements, natural menopause relief products, and scar tissue and cosmetic stretch mark creams under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, referred to as generic formulations, under its BocaGreenMD Prena1 name.
Open the TXMD Page at The Online Investor »

Company Name:  TherapeuticsMD, Inc.
Website:  www.therapeuticsmd.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding TXMD:  14
Total Market Value Held by ETFs:  $18.00M
Total Market Capitalization:  $679.00M
% of Market Cap. Held by ETFs:  2.65%
 

Open the TXMD Page at The Online Investor (in a new window) »

August 1, 2014    1:45 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.